Role of STAT3 pathway in genitourinary tumors

Abstract

The STAT3 is often dysregulated in genitourinary tumors. In prostate cancer, STAT3 activation correlates with Gleason score and pathological stage and modulates cancer stem cells and epithelial-mesenchymal transition. In addition, STAT3 promotes the progression from carcinoma in situ to invasive bladder cancer and modulates renal cell carcinoma angiogenesis by increasing the expression of HIF1α and VEGF. STAT3 is also involved in the response to tyrosine kinase inhibitors sunitinib and axitinib, in patients with metastatic renal cell carcinoma, and to second-generation androgen receptor inhibitor enzalutamide in patients with advanced prostate cancer. In this review, we describe the role of STAT3 in genitourinary tumors, thus describing its potential for future therapeutic strategies.Regulation of the protein STAT3 is often dysfunctional in genitourinary tumors, including prostate, bladder and kidney cancer. STAT3 is involved in the generation of these tumors and has an effect in their response to treatments. In this review, we describe its role in genitourinary tumors and discuss its potential for use in future therapies.

In Vitro and In Vivo Antimetastatic Effect of Glutathione Disulfide Liposomes

“…30 STAT3 plays a role in regulating the expression of transcriptional factors that drive EMT and modulating cytoskeleton dynamic during the initiation stage of the EMT. 38 In addition, we also observed that treatment of cells with GSSG liposomes caused apoptosis in these cells. 30 …”

Activated STAT3 Could Reduce Survival in Patients with Esophageal Squamous Cell Carcinoma by Up-regulating VEGF and Cyclin D1 Expression

“…Signal transduction and activators of transcription factor (STAT) 3, a member of the STAT family, is frequently regarded as an oncogene [4][5][6]. STAT3 can be activated via phosphorylation events within the Janus kinase-STAT, producing tyrosine or serine phosphorylated STAT3 (p-STAT3) [7,8]. p-STAT3 is able to increase the expression levels of certain target genes, including vascular endothelial growth factor (VEGF), Cyclin D1 and Bcl-xL, etc [9][10][11][12].…”

Welcome to volume 2 of Future Science OA

“…'s case report demonstrating a need for more collaboration to ensure literature reviews are comprehensive [9], a new generic model to help the development of applications for clinical decision-making created by Tibor van Rooij and colleagues [10], an examination of the potential uses of the STAT3 pathway in genitourinary tumors [11], and, finally, a research article examining the potential of extracellular embryo genomic DNA for genotyping applications [12]. This content is merely a snapshot of our excellent articles, and once again we thank all of our authors for their efforts throughout the year.…”